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LETTERS TO THE EDITOR
Lack of TTC4 Mutations in Melanoma
To the Editor:
A combination of karyotypic (Thompson et al, 1995; Zhang et
al, 1999; Smedley et al, 2000) and loss of heterozygosity
(Dracopoli et al, 1989; Walker et al, 1995) analyses have shown
that the short arm of chromosome 1 is frequently deleted in
melanoma and other tumor types (reviewed in Schwab et al,
1996). In general, multiple regions of 1p are nonrandomly
affected, with the most common abnormalities in melanoma
affecting bands 1p36, 1p22±21, and 1p11. Thus there may be
multiple tumor suppressor genes on this chromosome arm.
Several candidates have already been tested, including p73, a
p53 homolog mapping to 1p36, in which no mutations have
been detected in melanoma (Tsao et al, 1999), and only
extremely rare changes in other cancers (Davis and Dowdy,
2001). To date, no chromosome 1p tumor suppressor gene
candidate associated with the development of a signi®cant
proportion of a particular cancer type has been identi®ed.
Su et al (1999) isolated a candidate tumor suppressor gene on
chromosome 1p31.3, a region frequently deleted in breast cancer.
The gene, termed TTC4, is a member of a family of genes that
contain tetratricopeptide repeat motifs. Members of this gene
family are involved in a diverse range of intracellular activities,
including cell cycle control, protein kinase inhibition, neuro-
genesis, and tumorigenesis (reviewed in Su et al, 2000). No TTC4
mutations were detected in a panel of 20 sporadic breast tumors
studied by Su et al (2000); however, the involvement of this gene in
melanoma development has been suggested by Poetsch et al (2000),
who analyzed a series of DNA from melanomas and precursor
lesions (35 naevi, 32 primary, and 25 metastatic tumors, and four
melanoma cell lines). Whereas no TTC4 mutations were detected
in the nevi, mutations causing amino acid substitutions predicted to
affect protein function were detected in four of 32 (12.5%) primary
melanomas, six of 25 (24%) metastatic melanomas, and one of four
(25%) cell lines. No TTC4 mutation was present in the patients'
corresponding constitutional DNA, thus indicating they occurred
as somatic events. Three polymorphisms were also detected
(T139A, C504T, and an insertion in intron 2), with frequencies
of 48%, 6%, and 3%, respectively. These nucleotide changes were
predicted to cause no change in the TTC4 protein product and all
three were observed in healthy controls.
Apart from CDKN2A and PTEN, no other tumour
suppressors have mutation frequencies as high as 25% in
melanomas; therefore, to assess further the role of TTC4
mutations in melanoma development, we sequenced the
complete cDNA in a panel of 40 melanoma cell lines. These
lines were established in the laboratories of Dr Peter Parsons
and Dr Chris Schmidt at the Queensland Institute of Medical
Research (Royal Brisbane Hospital, QLD, Australia); all derived
from primary cutaneous melanomas or metastases thereof, and
are a subset of those described in Castellano et al (1997).
Primers were designed based on the published genomic
sequence (GenBank accession no. AF073887), taking into
account the corrected deduced amino acid sequence (with an
extra 31 amino acids at the carboxyl terminus of the protein)
described in Poetsch et al (2000). Using the primer pairs:
TTC270F: 5¢-GAA GGC AGG GCA TCA GCT CTG-3¢ and
TTC869R: 5¢-GCT TTA GCC CTC ATT TCC AG-3¢,
TTC777F: 5¢-CTG AAA CAC TTT GCC GAG G-3¢ and
TTCStopR: 5¢-CAG TAT GTC CAG CTG ATT CAG-3¢,
we generated two overlapping polymerase chain reaction
fragments of 599 and 753 bp, respectively.
Polymerase chain reaction ampli®cation was performed in a ®nal
volume of 50 ml, containing 75 ng of DNA, 1 3 reaction buffer,
0.2 mM of deoxyribonucleoside triphosphate, 1.5 mM magnesium
chloride, and 1.25 units of TF1 DNA Polymerase (Fisher Biotech).
A ``touch-down'' protocol was employed, with an initial
denaturation at 94°C for 3 min, followed by two cycles of 94°C
for 60 s, 65°C for 90 s, and 72°C for 90 s, after which the
annealing temperature was decreased by 2°C every two cycles to
55°C, when 35 cycles were performed, followed by a ®nal
extension of 72°C for 5 min. Polymerase chain reaction products
were puri®ed from 2% agarose gels using a QiaQuick Gel
Puri®cation Kit (Qiagen). Sequence reactions employed the
original primers under the following thermocycler conditions: 25
cycles of 96°C for 30 s, 50°C for 15 s, and 60°C for 4 min, prior to
electrophoresis and analysis on an ABI Prism 377 DNA
sequencer. Sequences were compared with the GenBank database
sequence using Bionavigator EclustalW program (http://www.
bionavigator.com) and BLASTN (http://www.ncbi.nlm.nih.gov/
BLAST).
Although we detected two of the polymorphisms reported by
Poetsch et al (2000), we found no other changes in the TTC4
open reading frame. The complete cDNA ampli®ed faithfully in
two overlapping fragments for all samples, indicating there were
no intragenic deletions, nor intronic mutations affecting splicing.
The ®nding that > 61% of cell lines analyzed carried one or
other polymorphism also provides evidence that large deletions
that remove the entire gene are uncommon. Similarly, they
argue that promoter mutations resulting in transcriptional
silencing of one allele is unlikely to be a signi®cant mechanism
of TTC4 inactivation. In contrast, Poetsch et al (2000) found
mutations in 11 of 61 (18%) of melanoma-derived samples
(fresh tumors and cell lines). Because some of our lines are
hemizygous for chromosome 1p, we cannot completely pre-
clude the possibility of a role for TTC4 haploinsuf®ciency in
melanoma development, nor a role for dominant-negative
acting mutations present in vivo, which must be lost for
propagation in culture. Both scenarios seem very unlikely,
however, given that one primary melanoma and all metastases
in the German study had lost the wild-type allele, indicating
that if TTC4 plays a part in melanoma development it is via
loss-of-function characteristic of classical tumor suppressors.
Reasons for the discrepancy in TTC4 somatic mutation
frequencies between the two studies (0% vs 18%) may include
our failure to detect point mutations in our study, differences in
ethnicity of the two populations, and different environmental
factors. As we reliably detected the two most common TTC4
polymorphisms, it is unlikely that we missed other mutations.
Frequencies of these polymorphisms (T139A and C504T) were
48% and 6%, respectively, in the samples from north-eastern
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Germany studied by Poetsch et al (2000), compared with 61% (49
of 80 chromosomes) and 5% (four of 80 chromosomes) in the
Australian samples in our study. The similarity in polymorphism
frequencies indicates that there is no signi®cant difference in
genetic background between the two populations that may account
for the major difference in reported mutation frequency. It is not
known whether differences in environment could account for the
discrepancy; however, it is dif®cult to envisage how the major
environmental risk factor for melanoma development (exposure to
ultraviolet radiation; Whiteman and Green, 1999) could contribute
to the difference. Unless one invokes an environmental carcinogen
other than ultraviolet radiation, it seems more likely that there
would be less somatic mutations detected in north-eastern
Germany than in Australia.
Overall, in stark contrast to the study of Poetsch et al (2000),
our results do not indicate a signi®cant role for TTC4
mutations in melanoma development. Although TTC4 initially
appeared a good candidate, the search for tumor suppressor
genes on 1p continues.
This work was supported by the National Health and Medical Research Council.
Nicole Irwin, Graeme Walker, Nicholas Hayward
Queensland Institute of Medical Research,
P.O. Royal Brisbane Hospital, QLD 4029, Australia
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Expression of the 90K Tumor-Associated Protein in Benign
and Malignant Melanocytic Lesions
To the Editor:
Histopathologic differentiation of melanoma from benign melano-
cytic lesions can be extremely dif®cult (Barnhill et al, 1999; Reed,
1999), as a subset of melanomas mimic conventional (Suster et al,
1987; Wong et al, 1995) or Spitz's nevi (Muhlbauer et al, 1983;
Smith et al, 1989; Wong et al, 1995), but behave aggressively (Reed
et al, 1975; Reed, 1978; Muhlbauer et al, 1983; Phillips et al, 1986).
Therefore, the identi®cation of molecular markers that allow an
accurate diagnosis of melanoma is of utmost importance. Studying
such markers could also improve the understanding of the biologic
events involved in the melanocyte transformation to a highly
invasive and metastatic tumor. 90K is a large oligomeric protein
composed of a » 90 kDa subunit, originally identi®ed as a tumor-
secreted antigen in the culture medium of human breast cancer cells
(Iacobelli et al, 1986). After cDNA cloning (Ullrich et al, 1994), the
sequence of 90K showed that it contained a cystein-rich domain,
which is homologous to that found in the SRCR group A family of
proteins and is strictly related to the immunoglobulin superfamily
(Resnick et al, 1994). 90K was identi®ed independently as a ligand
of the lactose-speci®c S-type lectin, galectin-3 (formerly known as
Mac-2), and also named Mac-2 binding protein (Koths et al, 1993).
90K is observed in many tissues and in biologic ¯uids (Koths et al,
1993; D'Ostilio et al, 1996) and is overexpressed by the majority of
human tumors (Iacobelli et al, 1986), with serum levels frequently
elevated, as in patients with melanoma (Natoli et al, 1994). In A375
Table I. 90K staining in benign and malignant melanocytic
lesions
Cases
Total cases
(no.)
Positive
cases (no.)
Distribution
pattern Score
Lentigo simplex 5 0
Junctional nevus 5 2 Diffuse +/±
Intradermal nevus 5 1 Focal +/±
Compound nevus 10 5 Focal (2)
Patchy (3)
+/±
Spitz's nevus 10 10 Diffuse +/++
Metastasizing
Spitz's nevus
2 2 Focal (1)
Diffuse (1)
+/++
Melanoma in nevusa 9 9 Diffuse ++/+++
In situ melanoma 6 6 Diffuse +++
Melanoma < 0.76 mm 16 16 Diffuse (12)
Patchy (4)
++/+++
Melanoma > 0.76 to
< 3.00 mm
Melanoma > 3.00 mm
14
8
14
8
Diffuse (10)
Patchy (4)
Diffuse (4)
Patchy (4)
++/+++
++/+++
Cutaneous metastasis 6 6 Diffuse +/++
Nodal metastasis 3 3 Diffuse +/++
Bone metastasis 1 1 Focal ++
aResidual nevi were negative.
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